Your SlideShare is downloading. ×
  • Like
Talk: Hypomethylating Agent in Patients with MDS
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Talk: Hypomethylating Agent in Patients with MDS

  • 532 views
Published

Talk on MDS and Hypomethylating agents in Kuala Lumpur

Talk on MDS and Hypomethylating agents in Kuala Lumpur

Published in Health & Medicine , Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
532
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
5
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Cordially invites you to attend a Dinner Lecture “How to use Hypomethylating Agent in Patients with MDS: Focus on Treatment Schedule and Prevention of Side Effect” International Speaker Chairperson Dr Antonio Pinto Dato’ Dr Chang Kian Meng Head, Hematology/Oncology Unit Head, Department of Haematology National Cancer Institute Hospital Ampang Fondazione ‘Pascale’ President Head, Department of Hematology Malaysian Society of Haematology Istituto Pascale IRCCS, Naples, Italy Date: March 8, 2011 (Tuesday) Time: 1900- 2200 hrs Venue: Hilton Kuala Lumpur Suite 2 & 3, Level 7Dr. Antonio Pinto graduated in Medicine in 1981 and obtained the Specialty Board Certification in Oncology andin Clinical Hematology. He gained clinical and research experience during different training periods inOncology/Hematology in the UK (University of London, St. Thomas’ Hospital, Northwick Park Hospital;University of Glasgow) and Australia (University of Melbourne, Ludwig Institute for Cancer Research). Dr. Pintojoined in 1987 the Centro di Riferimento Oncologico, Aviano, Italy where he served as Head of theDevelopmental Oncology/Hematology and Leukemia Unit up to November 2000. From December 2000 to date,he is serving as Head of the Hematology/Oncology Unit of the National Cancer Institute, Fondazione ‘Pascale’,IRCCS, Naples, Italy. Starting from march 2008 he was appointed as Head of the new Department ofHematology at the Istituto Pascale, IRCCS, Naples, Italy. Dr. Pinto has published several studies addressing therelevance of cell contact-dependent and cytokine-mediated interactions between Reed-Sternberg cells andreactive cell populations in tissues involved by Hodgkin’s disease.He has also unveiled the role of some TNF-superfamily receptors and ligands and of CD138 (Syndecan-1) inhuman leukemias and Hodgkin’s lymphoma. He concurrently coordinated the clinical development in Europe ofDNA-methyltransferases inhibitor 5-aza-2’-deoxycytidine (Decitabine) by designing and conducting phase I andII trials in leukemia and myelodysplastic syndromes, becaming member of the international working group (IWG)for response criteria in myelodysplasia. Dr. Pinto currently coordinates phase II trials on newer upfront andsalvage regimes for Hodgkin’s and non-Hodgkin lymphoma and GCP phase III studies with upfront experimentalregimes in lymphomas and multiple myeloma. He acted as member of the National Comittee for Evaluation of Supported by anPhase I Clinical Trials (Commissione Ministeriale per laccertamento dei requisiti dei prodotti farmaceutici di educationalnuova istituzione, ex art.7 D.P.R. 439/2001) and of the Working Party for non conventional cancer treatments, grant fromConsiglio Superiore di Sanità, National Ministry of Health, Rome, Italy. Dr. Pinto authored more than 160 paperson high-rank international journals, with a personal IF > 650. Buffet Dinner will be provided. Limited seats available. • RSVP • by March 01, 2011 • Wong Chee Keong: +65 9177 4866 / ckwong@celgene.com • • Juls: +65 6572 5131 / jbjalil@celgene.com •
  • 2. SPEAKER AND TITLE TIMERegistration 19:00-19:30DR ANTONIO PINTOHow to use Hypomethylating Agent in Patients with MDS: 19:30-20:10Focus Treatment Schedule and Prevention of Side EffectQ&A 20:10-20:30 20:30DINNER onwards